Affected individuals with gynecologic cancer have brand-new optimism in a original technology now offered at the Seidman Cancer Center at University Hospitals Case Medical Center. A team of cancer specialists, led by Robert DeBernardo, MD, is among the first in the nation to launch a dedicated program using Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat ovarian, endometrial and select other cancers.
Carried out promptly following surgery, HIPEC makes available heated chemotherapy through a ‘hot bath’ into the abdominal cavity, where it can penetrate diseased tissue directly. Once the physician takes away all of the visible cancer as workable, a heated, a sterilized chemotherapy solution is distributed all through the abdominal area through a technically sophisticated perfusion process to destroy the surviving cancer cells.
“This is a new and potentially revolutionary way of treating women with gynecologic cancers, which tend to be quite responsive to chemotherapy,” says Dr. DeBernardo, gynecologic oncologist at UH Case Medical Center and Assistant Professor at Case Western Reserve University School of Medicine. “Our preliminary data and experience has been overwhelmingly positive and the therapy has been well-tolerated and effective. HIPEC promises to extend lives in a meaningful way.”
HIPEC has been used for years for public health care in patients with colon, pseudomyxomas, malignant mesothelioma and appendiceal cancer, cancers that generally speaking aren’t reactive to chemotherapy, but it’s now seen as an encouraging brand new therapy for gynecologic malignancy.